Skip Navigation



Carcinogenesis Advance Access published online on May 2, 2008
Carcinogenesis, doi:10.1093/carcin/bgn107
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
29/9/1781    most recent
bgn107v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Van Dyke, A. L.
Right arrow Articles by Schwartz, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Dyke, A. L.
Right arrow Articles by Schwartz, A. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

COX-2/EGFR Expression and Survival among Women with Adenocarcinoma of the Lung

Alison L. Van Dyke1, Michele L. Cote2,3, Geoffrey Prysak2, Gina B. Claeys2, Angie S. Wenzlaff2, Valerie Murphy2, Fulvio Lonardo4,5 and Ann G. Schwartz2,3

1 Cancer Biology Program, Wayne State University School of Medicine, (Detroit, Michigan)
2 Population Studies and Prevention Program, Karmanos Cancer Institute, Wayne State University School of Medicine (Detroit, Michigan)
3 Department of Internal Medicine, Wayne State University School of Medicine, (Detroit, Michigan)
4 Department of Pathology, Wayne State University School of Medicine (Detroit, MI)
5 Developmental Therapeutics Program, Karmanos Cancer Institute (Detroit, MI)

Alison L Van Dyke, Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, Phone: 313-578-4314, Fax: 313-578-4306, Email: avandyk{at}med.wayne.edu

Previous studies suggest cyclooxygenase-2 (COX-2) expression may predict survival among patients with non-small cell lung cancer (NSCLC). COX-2 may interact with epidermal growth factor receptor (EGFR) suggesting that combined COX-2/EGFR expression may provide predictive value. The extent to which their independent or combined expression is associated with prognosis in women with adenocarcinoma of the lung is unknown. In the present study, we examined relationships between COX-2 expression (n = 238), EGFR expression (n = 158), and dual COX-2/EGFR expression (n = 157) and survival among women with adenocarcinoma of the lung. Overall survival was estimated by constructing Cox proportional hazards models adjusting for other significant variables and stratifying by stage at diagnosis and race. Clinical or demographic parameters were not associated with either COX-2 or EGFR expression. Patients with COX-2 positive tumors tended to have poorer prognosis than did patients with COX-2 negative tumors (HR 1.67; 95% CI 1.01-2.78). African Americans with COX-2 positive tumors had a statistically nonsignificant higher risk of death than African Americans with COX-2 negative tumors (HR 5.58; 95% CI 0.64-48.37). No association between COX-2 expression and survival was observed among Caucasians (HR 1.29; 95% CI 0.72-2.30). EGFR expression was associated with a 44% reduction in the risk of death (HR 0.56; 95% CI 0.32-0.98). COX-2-/EGFR+ tumor expression, but not COX-2+/EGFR+ tumor expression, was associated with survival when compared with other combined expression results. In conclusion, COX-2 and EGFR expression, but not combined COX-2+/EGFR+ expression, independently predict survival of women with adenocarcinoma of the lung.

Key Words: COX-2 • EGFR • adenocarcinoma • lung • survival • women

Received January 31, 2008; revised April 24, 2008; accepted April 25, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.